Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Adagene, Sanofi ink $2.5b deal for cancer solutions

    By ZHOU WENTING in Shanghai | China Daily | Updated: 2022-03-03 09:48
    Share
    Share - WeChat
    Visitors gather at Sanofi's booth during the fourth China International Import Expo in Shanghai in November. [Provided to China Daily]

    China's Adagene Inc, a Nasdaq-listed innovative biopharmaceutical company focusing on discovery and development of antibody-based novel cancer immunotherapy, announced collaboration and inked an exclusive license agreement with Sanofi for $2.5 billion on Wednesday, the company said.

    According to the deal, Adagene will authorize its core technology to Sanofi and help it create new medicines. The potential transaction value to be seen through such cooperation between the domestic biopharmaceutical enterprise with its partner hit a record in its field, said industry insiders.

    "Original biopharmaceutical developments from China are attracting rising international attention, and new drugs that can truly solve unmet clinical medical needs will always be the pursuit of innovation," Luo Peizhi, co-founder and CEO of Adagene, said during an exclusive interview with China Daily.

    The agreement said Adagene, founded in Suzhou, Jiangsu province in 2012, will be responsible for early-stage research activities to develop versions of Sanofi candidate antibodies, using Adagene's proprietary technology. Sanofi will be responsible for later-stage research and clinical, product development and commercialization activities.

    "We look forward to working with Adagene to design antibodies that can help us bring transformative new medicines to people living with cancer," said Valeria Fantin, global head of oncology research at Sanofi.

    "Adagene's antibody platform is expected to help us precisely target established, but poorly addressed oncology mechanisms with best-in-class medicines," she said.

    Luo said the proprietary technology is a precision antibody masking platform designed to enable the antibody to bind to its target specifically only after conditional activation of the antibody in target tissues.

    By engineering and developing therapeutic antibody candidates to selectively activate in the tumor microenvironment, the platform is designed to improve safety and tolerability of antibody therapeutics while maintaining clinical activity.

    "This core technology from us has been proven through extensive preclinical and clinical data. So far, a very limited number of companies can develop and apply such technology with clinically validated efficacy," Luo said.

    Raymond Tam, chief financial officer of Adagene, said the company's gains from the authorization are fairly competitive in terms of both upfront fees and total potential milestone payments. The company will also get tiered royalties on future global net sales, he said.

    Industry observers said that China is expected to enter the world's first echelon in new drug research and development within the next decade, and multinational pharmaceutical giants are deepening collaboration with local players in recent years.

    The United States Food and Drug Administration on Monday approved CAR-T, a tumor immunotherapy, to treat adults with multiple myeloma. The medicine was a potentially best-in-class innovative tumor drug developed by Nanjing-based Legend Biotech. Later, Janssen Pharmaceutical joined in its development.

    Last month, US-based Eli Lilly, which reached deals with more than 10 Chinese pharmaceutical enterprises in clinical development projects among others over the past decade, established its China innovation incubation platform in Shanghai's Zhangjiang High-Tech Park to join hands with more partners to create original medications from local sources.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    中文亚洲AV片在线观看不卡| 免费无码国产在线观国内自拍中文字幕| 日韩精品久久无码人妻中文字幕| 无码中文字幕av免费放dvd| 人妻AV中文字幕一区二区三区| 69久久精品无码一区二区| 中文字幕无码日韩专区免费| 日韩精品久久无码中文字幕| 老子影院午夜精品无码| 精品欧洲av无码一区二区三区| 熟妇女人妻丰满少妇中文字幕| AV色欲无码人妻中文字幕| 久久亚洲精品无码AV红樱桃| 国产在线无码精品电影网| 中文字幕成人精品久久不卡| 日韩一本之道一区中文字幕| 精品无码久久久久久国产| 国产av无码专区亚洲av桃花庵| 亚洲AV无码国产精品色午友在线| 久久无码专区国产精品发布| 日韩欧美中文字幕一字不卡| 暖暖免费在线中文日本| 亚洲一区二区三区在线观看精品中文| 亚洲AV无码一区二区一二区| 精品久久久久久无码人妻蜜桃| 国产精品亚洲аv无码播放| 久久亚洲精品成人av无码网站| 色窝窝无码一区二区三区色欲| 亚洲av中文无码乱人伦在线播放 | 无码乱人伦一区二区亚洲| 亚洲午夜福利AV一区二区无码| 免费无码黄网站在线看| 日韩av无码免费播放| 国产成人无码一二三区视频| 久久无码AV中文出轨人妻| 国产成人无码AV一区二区在线观看| 中文字幕在线看日本大片| 日本无码小泬粉嫩精品图| 13小箩利洗澡无码视频网站免费| 曰批全过程免费视频在线观看无码 | 天堂√最新版中文在线|